ArticlePloS one2013
Myriocin significantly increases the mortality of a non-mammalian model host during Candida pathogenesis.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 46 citations in OpenAlex.
- Evolution, structure and function of the putative biosynthetic gene cluster of the fungal secondary metabolite myriocin, a potent inhibitory sphingolipid.Communications biology · 2026Article
- Prophylactic oral Limosilactobacillus fermentum DSM 34872 protects Galleria mellonella from gut-associated pathogens.BMC microbiology · 2026Article
- Peptides fromFuture microbiology · 2025Article
- Article
- Comparative genomics of Metarhizium brunneum strains V275 and ARSEF 4556: unraveling intraspecies diversity.G3 (Bethesda, Md.) · 2024Article
- Human breast milk isolated lactic acid bacteria: antimicrobial and immunomodulatory activity on theFrontiers in cellular and infection microbiology · 2024Article
- Article
- Review
- Article
- Sphingolipid Inhibitors as an Alternative to Treat Candidiasis Caused by Fluconazole-Resistant Strains.Pathogens (Basel, Switzerland) · 2021Article
- Membrane disruption of Fusarium oxysporum f. sp. niveum induced by myriocin from Bacillus amyloliquefaciens LZN01.Microbial biotechnology · 2021Article
- Mechanistic Understanding ofFrontiers in microbiology · 2021Review
- Fungal sphingolipids: role in the regulation of virulence and potential as targets for future antifungal therapies.Expert review of anti-infective therapy · 2020Review
- Interplay between Fungal Infection and Bacterial Associates in the Wax MothJournal of fungi (Basel, Switzerland) · 2020Article
- Galleria mellonella as a consolidated in vivo model hosts: New developments in antibacterial strategies and novel drug testing.Virulence · 2019Review
- Sphingolipid biosynthetic pathway is crucial for growth, biofilm formation and membrane integrity ofFuture medicinal chemistry · 2019Article
- The AGC Kinase YpkA Regulates Sphingolipids Biosynthesis and Physically Interacts With SakA MAP Kinase inFrontiers in microbiology · 2018Article
- Sphingolipids as targets for treatment of fungal infections.Future medicinal chemistry · 2016Review
- Antifungal activity of Myriocin on clinically relevant Aspergillus fumigatus strains producing biofilm.BMC microbiology · 2015Article
- Sphingolipids as Regulators of the Phagocytic Response to Fungal Infections.Mediators of inflammation · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida albicans is a major human pathogen whose treatment is challenging due to antifungal drug toxicity, drug resistance and paucity of antifungal agents available. Myrocin (MYR) inhibits sphingosine synthesis, a precursor of sphingolipids, an important cell membrane and signaling molecule component. MYR also has dual immune suppressive and antifungal properties, potentially modulating mammalian immunity and simultaneously reducing fungal infection risk. Wax moth (Galleria mellonella) larvae, alternatives to mice, were used to establish if MYR suppressed insect immunity and increased survival of C. albicans-infected insects. MYR effects were studied in vivo and in vitro, and compared alone and combined with those of approved antifungal drugs, fluconazole (FLC) and amphotericin B (AMPH). Insect immune defenses failed to inhibit C. albicans with high mortalities. In insects pretreated with the drug followed by C. albicans inoculation, MYR+C. albicans significantly increased mortality to 93% from 67% with C. albicans alone 48 h post-infection whilst AMPH+C. albicans and FLC+C. albicans only showed 26% and 0% mortalities, respectively. MYR combinations with other antifungal drugs in vivo also enhanced larval mortalities, contrasting the synergistic antifungal effect of the MYR+AMPH combination in vitro. MYR treatment influenced immunity and stress management gene expression during C. albicans pathogenesis, modulating transcripts putatively associated with signal transduction/regulation of cytokines, I-kappaB kinase/NF-kappaB cascade, G-protein coupled receptor and inflammation. In contrast, all stress management gene expression was down-regulated in FLC and AMPH pretreated C. albicans-infected insects. Results are discussed with their implications for clinical use of MYR to treat sphingolipid-associated disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.